Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BDX Stock Forecast 2025-2026
$175.97
Current Price
$50.43B
Market Cap
Buy 6
Hold 11
Sell 0
Wall St Analyst Ratings
Distance to BDX Price Targets
+82.2%
To High Target of $320.55
+11.4%
To Median Target of $196.00
-2.3%
To Low Target of $172.00
BDX Price Momentum
+1.7%
1 Week Change
+2.2%
1 Month Change
-23.2%
1 Year Change
-22.4%
Year-to-Date Change
-30.2%
From 52W High of $251.99
+7.7%
From 52W Low of $163.33
📊 TOP ANALYST CALLS
Did BDX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if BD is one of their latest high-conviction picks.
Latest BDX Stock Price Targets & Analyst Predictions
Based on our analysis of 24 Wall Street analysts, BDX has a neutral consensus with a median price target of $196.00 (ranging from $172.00 to $320.55). The overall analyst rating is Buy (7.2/10). Currently trading at $175.97, the median forecast implies a 11.4% upside. This outlook is supported by 6 Buy, 11 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BDX Analyst Ratings
6
Buy
11
Hold
0
Sell
BDX Price Target Range
Low
$172.00
Average
$196.00
High
$320.55
Current: $175.97
Latest BDX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BDX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 3, 2025 | Barclays | Matt Miksic | Overweight | Maintains | $241.00 |
| May 22, 2025 | Citigroup | Joanna Wiensch | Neutral | Downgrade | $185.00 |
| May 6, 2025 | Morgan Stanley | Patrick Wood | Overweight | Maintains | $196.00 |
| May 2, 2025 | Piper Sandler | Jason Bednar | Neutral | Downgrade | $185.00 |
| May 2, 2025 | Stifel | Rick Wise | Buy | Maintains | $224.00 |
| May 1, 2025 | William Blair | Brian Weinstein | Market Perform | Downgrade | $0.00 |
| May 1, 2025 | Citigroup | Buy | Maintains | $0.00 | |
| Apr 23, 2025 | Piper Sandler | Jason Bednar | Overweight | Maintains | $260.00 |
| Apr 7, 2025 | Barclays | Travis Steed | Overweight | Maintains | $261.00 |
| Feb 14, 2025 | Barclays | Travis Steed | Overweight | Maintains | $279.00 |
| Jan 28, 2025 | Piper Sandler | Jason Bednar | Overweight | Maintains | $280.00 |
| Jan 22, 2025 | Barclays | Overweight | Maintains | $0.00 | |
| Oct 1, 2024 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $290.00 |
| Oct 1, 2024 | Citigroup | Joanna Wiensch | Buy | Upgrade | $275.00 |
| Aug 2, 2024 | Raymond James | Jayson Bedford | Outperform | Maintains | $270.00 |
| Jul 26, 2024 | Stifel | Rick Wise | Buy | Maintains | $280.00 |
| Jul 11, 2024 | Citigroup | Neutral | Maintains | $0.00 | |
| Jul 10, 2024 | Citigroup | Joanna Wiensch | Neutral | Maintains | $255.00 |
| Jul 2, 2024 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $285.00 |
| May 30, 2024 | Goldman Sachs | David Roman | Buy | Initiates | $274.00 |
Becton, Dickinson and Company (BDX) Competitors
The following stocks are similar to BD based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
BDX
Becton Dickinson
mkt cap
50.43B
Becton, Dickinson and Company (BDX) Financial Data
Becton, Dickinson and Company has a market capitalization of $50.43B with a P/E ratio of 34.1x. The company generates $20.87B in trailing twelve-month revenue with a 7.2% profit margin.
Revenue growth is +4.5% quarter-over-quarter, while maintaining an operating margin of +16.0% and return on equity of +5.9%.
Valuation Metrics
Market Cap
$50.43B
Enterprise Value
$67.96B
P/E Ratio
34.1x
PEG Ratio
11.2x
Price/Sales
2.4x
Growth & Margins
Revenue Growth (YoY)
+4.5%
Gross Margin
+42.8%
Operating Margin
+16.0%
Net Margin
+7.2%
EPS Growth
-42.6%
Financial Health
Cash/Price Ratio
+1.4%
Current Ratio
1.1x
Debt/Equity
76.3x
ROE
+5.9%
ROA
+3.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Becton, Dickinson and Company (BDX) Business Model
About Becton, Dickinson and Company
What They Do
Develops and manufactures medical devices and systems.
Business Model
The company operates through three main segments: BD Medical, BD Life Sciences, and BD Interventional, generating revenue by providing a wide range of medical devices, instrument systems, and reagents to healthcare professionals and organizations. BD's products enhance patient safety and streamline healthcare delivery, thereby supporting various sectors, including pharmaceuticals and clinical laboratories.
Additional Information
Headquartered in Franklin Lakes, New Jersey, BD is a global leader in healthcare innovation, committed to advancing patient care and addressing healthcare challenges worldwide.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
70,000
CEO
Mr. Thomas E. Polen Jr.
Country
United States
IPO Year
1983
Website
www.bd.comBecton, Dickinson and Company (BDX) Latest News & Analysis
Latest News
BD Appoints Bilal Muhsin as Executive Vice President and President of Future Connected Care Segment
6 days ago
Quick Summary
BD (Becton, Dickinson and Company) appointed Bilal Muhsin as executive VP and president of the new Connected Care segment, effective July 2, as part of its New BD strategy.
Why It Matters
Leadership changes at BD signal a strategic shift towards Connected Care, potentially impacting innovation, market position, and investor confidence in future growth.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Investors are advised to consider dividend stocks with strong fundamentals and high yields as a favorable investment opportunity in the second half of 2025.
Why It Matters
The emphasis on dividend stocks with strong fundamentals and high yields signals potential for stable income and growth, attracting investors seeking reliable returns amid market uncertainties.
Source: 24/7 Wall Street
Market Sentiment:
Positive
Best Dividend Aristocrats For July 2025
15 days ago
Quick Summary
In 2025, Dividend Aristocrats (NOBL) gained 1.77%, underperforming the S&P 500 (SPY) at 5.55%. 44 of 69 Aristocrats raised payouts, with an average growth of 4.86%. 21 Aristocrats may offer 10% long-term returns.
Why It Matters
Underperformance of Dividend Aristocrats versus the S&P 500 highlights potential value opportunities. Healthy dividend growth and undervalued stocks could attract long-term investors seeking returns.
Source: Seeking Alpha
Market Sentiment:
Positive
New vaccine panel meeting underway
17 days ago
Quick Summary
CNBC's Angelica Peebles reports on vaccine developments during an appearance on 'Squawk on the Street.'
Why It Matters
Vaccine news can impact healthcare stock valuations, public sentiment, and economic recovery pace, influencing investment strategies and market volatility.
Source: CNBC Television
Market Sentiment:
Neutral
Quick Summary
Becton Dickinson (BDX) shares are in the 17th phase of the Adhishthana Cycle, indicating potential underperformance and consolidation until early June 2027, per proprietary analysis.
Why It Matters
Becton Dickinson's shares are poised for underperformance until mid-2027, suggesting potential stagnation and risk for investors considering this stock.
Source: Benzinga
Market Sentiment:
Negative
Best Dividend Kings: June 2025
20 days ago
Quick Summary
Year-to-date, Dividend Kings underperformed the S&P 500, but 26 are set to outperform in 2025, with a 5.19% growth rate. Seventeen are deemed undervalued with expected returns of at least 10%.
Why It Matters
Dividend Kings show resilience with healthy growth and undervaluation, suggesting potential for long-term gains despite recent underperformance. Positive returns in 2025 indicate recovery prospects.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About BDX Stock
What is Becton, Dickinson and Company's (BDX) stock forecast for 2026?
Based on our analysis of 24 Wall Street analysts, Becton, Dickinson and Company (BDX) has a median price target of $196.00. The highest price target is $320.55 and the lowest is $172.00.
Is BDX stock a good investment in 2026?
According to current analyst ratings, BDX has 6 Buy ratings, 11 Hold ratings, and 0 Sell ratings. The stock is currently trading at $175.97. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BDX stock?
Wall Street analysts predict BDX stock could reach $196.00 in the next 12 months. This represents a 11.4% increase from the current price of $175.97. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Becton, Dickinson and Company's business model?
The company operates through three main segments: BD Medical, BD Life Sciences, and BD Interventional, generating revenue by providing a wide range of medical devices, instrument systems, and reagents to healthcare professionals and organizations. BD's products enhance patient safety and streamline healthcare delivery, thereby supporting various sectors, including pharmaceuticals and clinical laboratories.
What is the highest forecasted price for BDX Becton, Dickinson and Company?
The highest price target for BDX is $320.55 from at , which represents a 82.2% increase from the current price of $175.97.
What is the lowest forecasted price for BDX Becton, Dickinson and Company?
The lowest price target for BDX is $172.00 from at , which represents a -2.3% decrease from the current price of $175.97.
What is the overall BDX consensus from analysts for Becton, Dickinson and Company?
The overall analyst consensus for BDX is neutral. Out of 24 Wall Street analysts, 6 rate it as Buy, 11 as Hold, and 0 as Sell, with a median price target of $196.00.
How accurate are BDX stock price projections?
Stock price projections, including those for Becton, Dickinson and Company, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2025 2:16 AM UTC